New bd reagents enable researchers to break through resolution boundaries in flow cytometry

Developed with novel dye technology and ai guidance, new bd horizon realyellow™ 586 reagents have potential to accelerate discovery and drug development in oncology, autoimmune disorders and infectious diseases franklin lakes, n.j. , april 25, 2022 /prnewswire/ -- bd (becton, dickinson and company) (nyse: bdx), a leading global medical technology company, today announced the launch of a new family of reagents that enables researchers to gain improved data resolution and greater insights from samples compared to traditional fluorochromes, made possible by their innovative development using novel dye technology and artificial intelligence (ai) guidance.
BDX Ratings Summary
BDX Quant Ranking